Whitehawk Therapeutics Capital Expenditures (CapEx) Growth & History (WHWK)
Whitehawk Therapeutics's capital expenditures (capex) was $552,000 for fiscal 2025.
View full Whitehawk Therapeutics company overviewWhitehawk Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $552,000 | −$1.1M | −66.63% |
| 2024 | 2024-12-31 | $1.7M | −$2.3M | −58.36% |
| 2023 | 2023-12-31 | $4.0M | $3.5M | +794.59% |
| 2022 | 2022-12-31 | $444,000 | $398,000 | +865.22% |
| 2021 | 2021-12-31 | $46,000 | $26,975 | +141.79% |
| 2020 | 2020-12-31 | $19,025 | −$217,927 | −91.97% |
| 2019 | 2019-12-31 | $236,952 | $199,040 | +525.01% |
| 2018 | 2018-12-31 | $37,912 | $29,016 | +326.17% |
| 2017 | 2017-12-31 | $8,896 | −$104,401 | −92.15% |
| 2016 | 2016-12-31 | $113,297 | — | — |
Whitehawk Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$1,000 | — |
| Q1 2026 | 2026-03-31 | $0 | −$551,000 | — |
| Q4 2025 | 2025-12-31 | $0 | −$186,000 | — |
| Q3 2025 | 2025-09-30 | $0 | −$188,000 | — |
| Q2 2025 | 2025-06-30 | $1,000 | −$540,000 | −99.82% |
| Q1 2025 | 2025-03-31 | $551,000 | −$188,000 | −25.44% |
| Q4 2024 | 2024-12-31 | $186,000 | −$630,000 | −77.21% |
| Q3 2024 | 2024-09-30 | $188,000 | −$910,000 | −82.88% |
| Q2 2024 | 2024-06-30 | $541,000 | −$148,000 | −21.48% |
| Q1 2024 | 2024-03-31 | $739,000 | −$630,000 | −46.02% |
| Q4 2023 | 2023-12-31 | $816,000 | $738,000 | +946.15% |
| Q3 2023 | 2023-09-30 | $1.1M | $996,000 | +976.47% |
| Q2 2023 | 2023-06-30 | $689,000 | $448,000 | +185.89% |
| Q1 2023 | 2023-03-31 | $1.4M | $1.3M | +5852.17% |
| Q4 2022 | 2022-12-31 | $78,000 | — | — |
| Q3 2022 | 2022-09-30 | $102,000 | $102,000 | — |
| Q2 2022 | 2022-06-30 | $241,000 | — | — |
| Q1 2022 | 2022-03-31 | $23,000 | — | — |
| Q3 2021 | 2021-09-30 | $0 | −$6,827 | — |
| Q3 2020 | 2020-09-30 | $6,827 | $2,546 | +59.47% |
| Q4 2019 | 2019-12-31 | $1 | −$8,531 | −99.99% |
| Q3 2019 | 2019-09-30 | $4,281 | −$16,601 | −79.50% |
| Q2 2019 | 2019-06-30 | $119,389 | $119,389 | — |
| Q1 2019 | 2019-03-31 | $113,283 | $104,785 | +1233.05% |
| Q4 2018 | 2018-12-31 | $8,532 | $6,183 | +263.22% |
| Q3 2018 | 2018-09-30 | $20,882 | $20,882 | — |
| Q2 2018 | 2018-06-30 | $0 | −$4,339 | — |
| Q1 2018 | 2018-03-31 | $8,498 | $6,290 | +284.87% |
| Q4 2017 | 2017-12-31 | $2,349 | $2,349 | — |
| Q3 2017 | 2017-09-30 | $0 | $0 | — |
| Q2 2017 | 2017-06-30 | $4,339 | $1,491 | +52.35% |
| Q1 2017 | 2017-03-31 | $2,208 | −$108,241 | −98.00% |
| Q4 2016 | 2016-12-31 | $0 | — | — |
| Q3 2016 | 2016-09-30 | $0 | — | — |
| Q2 2016 | 2016-06-30 | $2,848 | — | — |
| Q1 2016 | 2016-03-31 | $110,449 | — | — |
Whitehawk Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Whitehawk Therapeutics's capital expenditures (capex) increased from $19,025 to $552,000, a change of $532,975. The latest reported quarter, Q2 2026, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Whitehawk Therapeutics source filings ↗